Cardioprotective Effects of GLP-1 Receptor Agonists Beyond Glycemic Control

Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as key therapeutic agents in type 2 diabetes mellitus, with well-established benefits in glycemic control and weight reduction. However, accumulating evidence from large-scale cardiovascular outcome trials suggests that the benefits of GLP-1 RAs extend well beyond glucose lowering. These agents exert multiple cardioprotective effects through pleiotropic mechanisms involving endothelial function, inflammation, oxidative stress, and myocardial metabolism, positioning them as valuable tools in the management of patients with high cardiovascular risk. Methods and Results: This review synthesizes clinical and mechanistic data from randomized trials, observational cohorts, and translational studies evaluating the cardiovascular impact of GLP-1 RAs independent of glycemic modulation. Agents such as liraglutide, semaglutide, and dulaglutide have demonstrated significant reductions in major adverse cardiovascular events (MACE), particularly in patients with established atherosclerotic cardiovascular disease. Mechanistically, GLP-1 RAs improve endothelial nitric oxide bioavailability, reduce systemic inflammation by downregulating IL-6 and CRP, and attenuate myocardial ischemia-reperfusion injury through enhanced cardiomyocyte survival pathways. Additional benefits include reduction in blood pressure, improvement in lipid profiles, and decreased epicardial fat volume. Emerging data suggest favorable effects on heart failure hospitalization, particularly in HFpEF phenotypes. Preclinical models also reveal direct myocardial benefits, including improved mitochondrial efficiency and reduced fibrosis. Conclusion: GLP-1 receptor agonists confer broad cardioprotective effects that transcend glycemic regulation, with consistent benefits across diverse patient populations.